Short description
BioNTech is a biopharmaceutical company that develops cancer therapeutics for infectious diseases.
Description
BioNTech is a next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. It contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates.
Last funding
Cannot Access
Sign in for full access
Total funding
$$2020202
Sign in for full access
Location
Mainz, Rheinland-Pfalz, Germany, Europe
Founded on
January 1, 2008
Exited on
October 9, 2019
Went public on
October 9, 2019
Stock symbol
BNTX
Non-profit?
No
Acquired?
No
Revenue range
$7890 - 12340
Sign in for full access
Investors
Noaccess, Blurry Noaccess, Nopepepe, Noaccess, Nopepepe, Noaccessforu, Blurry Noaccess, Nopepepe, Blurry Noaccess, Uh Ohhhh, Noaccessforu, Blurry Noaccess, Noaccess, Uh Ohhhh, Absolutely Noaccess, Blurry Noaccess
Sign in for full access
Founders
Christoph Huber, Ugur Sahin, Özlem Türeci
Funding rounds count
5
Portfolio organisations count
Absolutely Noaccess, Absolutely Noaccess
Sign in for full access
Lead investments count
2
Exits count
No Way, Uh Ohhhh
Sign in for full access
IPO exits count
3